Comparison of the SF-36 Five-item Mental Health Inventory and Beck Depression Inventory for the screening of depressive symptoms in chronic dialysis patients

Tessa O. van den Beukel1,2, Carl E.H. Siegert1, Sandra van Dijk3, Pieter M. Ter Wee4, Friedo W. Dekker5 and Adriaan Honig6

1Department of Nephrology, Sint Lucas Andreas Hospital, Amsterdam, The Netherlands, 2Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands, 3Department of Medical Psychology, Leiden University Medical Center, Leiden, the Netherlands, 4Department of Nephrology, VU University Medical Center, Amsterdam, The Netherlands, 5Department of Psychiatry, Sint Lucas Andreas Hospital, Amsterdam, The Netherlands and 6Department of Psychiatry, VU University Medical Center, Amsterdam, The Netherlands

Correspondence and offprint requests to: Tessa O. van den Beukel; E-mail: tessa_van_den_beukel@hotmail.com

Abstract

Background. The Beck Depression Inventory (BDI) is a standard and validated questionnaire to screen for depressive symptoms in chronic dialysis patients, but is relatively extensive to use repeatedly in clinical practice. We investigated whether the five-item Mental Health Inventory (MHI-5) of the 36-item Short-Form Health Survey Questionnaire (SF-36) could be applied to screen for depressive symptoms in dialysis patients. Moreover, we determined the optimal MHI-5 cut-off score to assess depressive symptoms.

Methods. Chronic dialysis patients from three centres filled out the SF-36 and the BDI. A receiver operating characteristic (ROC) curve was constructed for the MHI-5 score with BDI \( \geq 16 \) as reference standard to (i) calculate the area under the curve to determine whether the MHI-5 could be considered as a useful screening instrument for depressive symptoms and (ii) proxy the optimal cut-off score of the MHI-5 to assess depressive symptoms. The optimal cut-off score was determined by the value for which the sum of sensitivity and specificity had an optimum.

Results. Of 133 included patients, 23% had depressive symptoms as determined with BDI \( \geq 16 \). The correlation of the BDI with MHI-5 was \(-0.64\). The area under the ROC curve was 0.82 (95% confidence interval 0.74–0.90). The optimal cut-off point of the MHI-5 was 70. MHI-5 \( \leq 70 \) had 77 sensitivity, 72 specificity, 44 positive predicting value and 91% negative predicting value with the presence of depressive symptoms determined with BDI \( \geq 16 \).

Conclusions. The MHI-5 may help clinicians to screen for depressive symptoms in dialysis patients without using an additional depression screening questionnaire once the SF-36 is completed. A cut-off value of 70 can be used safely for the purposes of screening applications.

Keywords: depressive symptoms; dialysis patients; mental health inventory; screening; SF-36

Introduction

Depression is the most common psychiatric disorder among chronic dialysis patients [1]. It is of great importance that depressive symptoms are successfully recognized and treated. Depressive symptoms diminish patient’s quality of life and are independently associated with an increased risk of hospitalization [2, 3]. In addition, depressive symptoms pose a risk factor for both cardiovascular and non-cardiovascular mortality [4–6]. Hence, the National Kidney Foundation, Disease Outcomes Quality Initiative (NKF KDOQI) guideline for cardiovascular disease in dialysis the patients recommends that the patient’s psychological state should be assessed at least biannually with specific focus on the presence of depressive symptoms [7].

The assessment of depressive symptoms is frequently performed using self-reported depression screening tools, whereupon patients who are screened positive are...
commonly examined more closely using diagnostic psychiatric interviews. A standard questionnaire to screen for depressive symptoms in chronic dialysis patients is the 21-item Beck Depression Inventory (BDI) [8–11]. The BDI has been validated in chronic dialysis patients and is therefore a reliable instrument to assess depressive symptoms in the dialysis population [9–12]. Although the BDI is frequently used, it is a relatively extensive screening tool to use repeatedly in clinical practice. It might be useful to identify brief and easy administered screening instruments that possess screening performances for depressive symptoms comparable to the BDI.

The five-item Mental Health Inventory (MHI-5) has been established as a simple and valid tool for detecting depressive symptoms in the general population and in different chronically ill patient populations [13–17]. The MHI-5 consists of five items and is known as the mental health subscale of the 36-item Short-Form Health Survey (SF-36) [18]. Among dialysis patients the SF-36 is frequently administered and consequently MHI-5 scores are widely available. Although the MHI-5 has been used before to indicate the presence of depressive symptoms in epidemiological studies among dialysis patients [19–23], to our knowledge the MHI-5 has not been validated as a screening tool for depressive symptoms in the dialysis population. This poses a problem for implementing the MHI-5 in clinical care. It is essential that measures are specifically evaluated to screen for depressive symptoms in dialysis patients since somatic symptoms of uraemia may overlap with depressive symptoms [24].

In the present study, we assessed the usefulness of the MHI-5 as a screening instrument for depressive symptoms in dialysis patients by comparing the MHI-5 with the standard, but relatively extensive, BDI questionnaire. In addition, we examined the optimal cut-off score of the MHI-5 for screening of depressive symptoms and investigated the usefulness of MHI-5 cut-off points that have been used so far in epidemiological studies among dialysis patients to indicate the presence of depressive symptoms.

Materials and methods

Patients

This cross-sectional study was performed among all end-stage renal disease (ESRD) patients treated with chronic haemodialysis or peritoneal dialysis in three dialysis centres: Sint Lucas Andreas Hospital, VU University Medical Center and Dialysis Center Diapriva, in Amsterdam, The Netherlands. Patients were eligible for study participation if they were at least 18 years of age, had ESRD for at least 30 days, were able to read the Dutch language and had no significant visual, physical or cognitive impairment that would prevent completion of the questionnaires. Patients gave written informed consent before inclusion. Patients who did not want to participate were asked to give written informed consent to obtain patient characteristics from medical records. The study was approved by the ethical committees of the participating centres.

Measures

All dialysis patients who fulfilled the inclusion criteria were invited to complete the validated Dutch translations of the BDI [12] and subsequently the SF-36 [25] during haemodialysis treatment or during a visit to the outpatient peritoneal dialysis clinic. The BDI consists of 21 items with four possible answers, measuring symptoms of depression over the previous week. The sum of the items results in a final score ranging from 0 to 63, with higher scores indicating more severe depressive symptoms. The MHI-5 consists of the following five questions: over the last 4 weeks, how often: (i) ‘Have you felt so down in the dumps that nothing could cheer you up?’, (ii) ‘Have you felt down- hearted and blue?’, (iii) ‘Have you been a happy person?’, (iv) ‘Have you felt a very nervous person?’ and (v) ‘Have you felt calm and peaceful?’. Each item has six possible responses ranging from ‘all the time’ (1 point) to ‘none of the time’ (6 points). The answers of the third and fifth question need to be reversed. The final MHI-5 score is calculated by summing up the item scores and transforming this score to a scale varying from 0 to 100, with lower scores indicating more severe depressive symptoms. For both the BDI and the MHI-5, the missing items were substituted by the mean score of the non-missing items.

Statistical analyses

Differences in patient characteristics between the participating and non-participating patients were analysed with t-tests for continuous variables and chi-square tests for categorical variables. We calculated the Pearson’s r correlation for the BDI score in relation to the MHI-5 score. R² was calculated to determine the explained variance. A BDI score ≥16 was chosen to indicate the presence of depressive symptoms which has 91% sensitivity and 86% specificity in dialysis patients with the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders Fourth Edition (DSM-IV) [11]. A receiver operating characteristic (ROC) curve for the MHI-5 score with BDI ≥16 as reference standard was constructed to calculate the area under the curve (AUC) with 95% confidence interval (CI) [26]. The AUC could be observed as the probability that a randomly selected patient with a BDI score ≥16 has a higher MHI-5 score than a randomly selected patient with a BDI score <16. If the AUC exceeds 0.80, the MHI-5 was considered as a useful screening instrument for depressive symptoms. Furthermore, the ROC curve was constructed to proxy the optimal cut-off score of the MHI-5 to assess depressive symptoms in dialysis patients [27, 28]. The optimal cut-off score was determined by the value for which the sum of sensitivity and specificity had an optimum. In this method, the sensitivity and specificity are considered equally important. However, the relative importance of the sensitivity and specificity depends largely on the purpose of use. Therefore, we depicted all cut-off values with corresponding sensitivities and specificities. Finally, we calculated sensitivity, specificity, positive predicting value (PPV) and negative predicting value (NPV) for BDI ≥16 compared with the optimal MHI-5 cut-off score determined in the ROC curve and several MHI-5 cut-off points previously used among dialysis patients. Cut-off points previously used included (i) MHI-5 cut-off score ≤52 (MHI-5 ≤52) [19, 23], (ii) a score of ≤3 to one of the items ‘Have you felt so down in the dumps that nothing could cheer you up?’ and ‘Have you felt a very nervous person?’ [20–22] and (iii) a score of ≤3 to both of these items (‘dumps or blue’) [21]. Significance levels were determined at P-value ≤0.05. The Statistical Package for Social Sciences (SPSS) version 18.0 was used for statistical analyses.

Sensitivity analysis

To test the robustness of our findings, two sensitivity analyses were performed. Firstly, a BDI cut-off score of ≥13 (BDI ≥13) was used to indicate the presence of depressive symptoms, since this value was found to be the optimal indicator of depressive symptoms among dialysis patients in the Netherlands (sensitivity 75 and specificity 90% for diagnosing depression) [12]. Secondly, we performed a sensitivity analysis using the Cognitive Depression Inventory (CDI) instead of the BDI. Six of 21 items of the BDI are related to somatic symptoms of depression, whereas the MHI-5 does not include somatic items. The CDI is a subset of the BDI, in which the six somatic items of the BDI are excluded. We used a CDI cut-off value of 10 (CDI ≥10), as this has been proposed to be a good predictor of depressive symptoms in dialysis patients (sensitivity 78 and specificity 81% for diagnosing depression in dialysis patients) [29, 30].

Results

Patient characteristics

Of the 170 patients eligible for study participation, 133 patients agreed to participate (78%). The patients...
responded to all MHI-5 items and BDI items, except for one patient who missed one MHI-5 item and two BDI items, one patient who missed two BDI items and one patient who missed one BDI item. Characteristics of the study sample are described in Table 1. The included patients were on average 62 years of age, were more often male (61%); 66% of the included patients were native Dutch and 72% were treated with haemodialysis. Nine per cent had previously been diagnosed with a depressive disorder and 6% of the patients were using an antidepressant during completion of the questionnaires. No statistically significant difference in characteristics presented in Table 1 was found between the participating and non-participating patients (data not shown).

### MHI-5 versus BDI

The Pearson’s $r$ correlation coefficient for the BDI score compared with the MHI-5 score was $-0.64$, indicating that 41% of the variance of the MHI-5 is explained by the BDI. Using BDI scores $\geq 16$ as measure of the presence of depressive symptoms, 23% of the patients were found to have depressive symptoms ($n = 30$). Figure 1 shows the ROC curve for the MHI-5 score compared with BDI $\geq 16$, with an AUC of 0.82 (95% CI 0.74–0.90). The maximum sum of sensitivity and specificity corresponds to the MHI-5 cut-off score of 70 (MHI-5 $\leq 70$) (Table 2). Using this cut-off score, 39% of the patients were found to have depressive symptoms ($n = 52$). Table 3 demonstrates sensitivities, specificities, PPVs and NPVs for the presence of depressive symptoms assessed with BDI $\geq 16$ as reference standard compared with MHI-5 $\leq 70$ and previously used MHI-5 related cut-off points. MHI $\leq 70$ had 77 sensitivity, 72 specificity, 44 PPV and 91% NPV. The previously used cut-off points of the MHI-5 had lower sensitivities and NPVs, but higher specificities and PPVs.

### Sensitivity analyses

Firstly, we used BDI scores $\geq 13$ instead of BDI scores $\geq 16$ to indicate the presence of depressive symptoms. The results did not materially differ compared with the primary analysis, although 33% instead of 23% of the patients were shown to have depressive symptoms ($n = 44$). The AUC for the MHI-5 score compared with BDI $\geq 13$ was

### Table 1. Characteristics of 133 chronic dialysis patients who completed the BDI and SF-36 questionnaires

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Participants ($n = 133$)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Demographic</strong></td>
<td></td>
</tr>
<tr>
<td>Age (years)</td>
<td>62 (16)</td>
</tr>
<tr>
<td>Sex, men (%)</td>
<td>61</td>
</tr>
<tr>
<td>Ethnicity, native Dutch (%)</td>
<td>66</td>
</tr>
<tr>
<td><strong>Clinical</strong></td>
<td></td>
</tr>
<tr>
<td>Duration on RRT (months)</td>
<td>54 (65)</td>
</tr>
<tr>
<td>Treatment modality, HD (%)</td>
<td>72</td>
</tr>
<tr>
<td>BMI (kg/m$^2$)</td>
<td>27 (6)</td>
</tr>
<tr>
<td>Primary kidney disease (%)</td>
<td></td>
</tr>
<tr>
<td>Diabetic nephropathy</td>
<td>16</td>
</tr>
<tr>
<td>Glomerulonephritis</td>
<td>13</td>
</tr>
<tr>
<td>Renal vascular disease</td>
<td>24</td>
</tr>
<tr>
<td>Co-morbidity (%)</td>
<td></td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>29</td>
</tr>
<tr>
<td>Cardiovascular disease*$^a$</td>
<td>44</td>
</tr>
<tr>
<td><strong>Laboratory investigations</strong></td>
<td></td>
</tr>
<tr>
<td>Haemoglobin (mmol/L)</td>
<td>7.2 (0.9)</td>
</tr>
<tr>
<td>Albumin (g/L)</td>
<td>37.0 (5.6)</td>
</tr>
<tr>
<td><strong>Psychiatric</strong></td>
<td></td>
</tr>
<tr>
<td>(Previous) diagnosed depressive disorder</td>
<td>9</td>
</tr>
<tr>
<td>(Previous) psychiatric disease*$^b$</td>
<td>13</td>
</tr>
<tr>
<td>Use of antidepressants</td>
<td>6</td>
</tr>
</tbody>
</table>

Values are presented as mean (SD) or percentage.

*$^a$Psychosis and/or tentamen suicidii and/or drug or alcohol abuse and/or other psychiatric disease.

*$^b$Myocardial infarction and/or angina pectoris and/or PTCA and/or CABG and/or congestive heart failure and/or peripheral vascular disease and/or CVA.

RRT, renal replacement therapy; HD, haemodialysis; BMI, body mass index; BDI, Beck Depression Inventory; MHI-5, five-item Mental Health Inventory.

### Table 2. Optimal cut-off points for the MHI-5 with BDI $\geq 16$ as reference standard

<table>
<thead>
<tr>
<th>Score</th>
<th>Sensitivity</th>
<th>Specificity</th>
</tr>
</thead>
<tbody>
<tr>
<td>7</td>
<td>0.00</td>
<td>1.00</td>
</tr>
<tr>
<td>18</td>
<td>0.03</td>
<td>1.00</td>
</tr>
<tr>
<td>30</td>
<td>0.07</td>
<td>1.00</td>
</tr>
<tr>
<td>34</td>
<td>0.13</td>
<td>1.00</td>
</tr>
<tr>
<td>38</td>
<td>0.17</td>
<td>1.00</td>
</tr>
<tr>
<td>42</td>
<td>0.23</td>
<td>1.00</td>
</tr>
<tr>
<td>46</td>
<td>0.27</td>
<td>0.98</td>
</tr>
<tr>
<td>50</td>
<td>0.30</td>
<td>0.97</td>
</tr>
<tr>
<td>54</td>
<td>0.40</td>
<td>0.93</td>
</tr>
<tr>
<td>58</td>
<td>0.50</td>
<td>0.89</td>
</tr>
<tr>
<td>62</td>
<td>0.57</td>
<td>0.84</td>
</tr>
<tr>
<td>66</td>
<td>0.67</td>
<td>0.78</td>
</tr>
<tr>
<td>70</td>
<td>0.77</td>
<td>0.72</td>
</tr>
<tr>
<td>74</td>
<td>0.83</td>
<td>0.65</td>
</tr>
<tr>
<td>78</td>
<td>0.90</td>
<td>0.54</td>
</tr>
<tr>
<td>82</td>
<td>0.93</td>
<td>0.45</td>
</tr>
<tr>
<td>84</td>
<td>0.97</td>
<td>0.34</td>
</tr>
<tr>
<td>86</td>
<td>0.97</td>
<td>0.33</td>
</tr>
<tr>
<td>90</td>
<td>0.97</td>
<td>0.30</td>
</tr>
<tr>
<td>94</td>
<td>1.00</td>
<td>0.20</td>
</tr>
<tr>
<td>98</td>
<td>1.00</td>
<td>0.15</td>
</tr>
<tr>
<td>100</td>
<td>1.00</td>
<td>0.00</td>
</tr>
</tbody>
</table>

*Fig. 1. Receiver operating characteristic curve for MHI-5 score against the BDI score cut-off $\geq 16$.*

*Table 3. Sensitivities, specificities, PPVs and NPVs for the presence of depressive symptoms assessed with BDI $\geq 16$ as reference standard compared with MHI-5 $\leq 70$ and previously used MHI-5 related cut-off points. MHI $\leq 70$ had 77 sensitivity, 72 specificity, 44 PPV and 91% NPV. The previously used cut-off points of the MHI-5 had lower sensitivities and NPVs, but higher specificities and PPVs.*
approximately the same [0.80 (95% CI 0.72–0.88)]. The optimal MHI-5 cut-off score was 74, with corresponding sensitivity of 75 and specificity of 69%. Secondly, we repeated the analysis using CDI scores ≥10 as the indicator of depressive symptoms. The results obtained in this analysis did not reveal different results: 23% of the patients were shown to have depressive symptoms (n = 31), the Pearson’s correlation coefficient for the CDI score compared with the MHI-5 score was −0.62 and the AUC for the MHI-5 score compared with CDI ≥10 was 0.81 (95% CI 0.73–0.90). The optimal MHI-5 cut-off score was found to be 74 (sensitivity 0.81, specificity 0.65).

### Discussion

To screen easily and effectively for depressive symptoms in dialysis patients brief, simple and well-accepted tools are asked for. In the present study, we investigated whether the widely administered MHI-5 questionnaire could be used to assess depressive symptoms in dialysis patients; therefore, we compared the MHI-5 with the standard BDI questionnaire. We found that the MHI-5 has high discrimination in screening for depressive symptoms and may, therefore, be considered as a useful screening tool for depressive symptoms in dialysis patients. This finding persisted in two sensitivity analyses.

The MHI-5 is frequently administered among dialysis patients because of its incorporation in the SF-36. The MHI-5 is originally designed to assess anxiety, depression, loss of behavioural or emotional control and psychological well-being [31]. Our finding that the MHI-5 may also be considered as helpful screening instrument for depressive symptoms is in line with studies among other populations [13–17] and may be important for clinical practice. In clinical practice, the patient’s psychological state needs to be assessed at least twice a year [7]. The MHI-5 might assist clinicians to screen for depressive symptoms without administering an additional questionnaire once the SF-36 is completed.

The optimal MHI-5 cut-off score to screen for depressive symptoms was found to be 70. In epidemiological studies among dialysis patients, a cut-off score of 52 has been used to assess the presence of depressive symptoms [19, 23]. This cut-off value was found to be the optimal value for detecting depressive symptoms in a study among the general population [31] and in a small study among HIV-seropositive outpatients [32]. Furthermore, scores of ≤3 to one or both of the MHI-5 items ‘down in the dumps’ and ‘downhearted and blue’ have been used as measures of depressive symptoms. In a previous study among 97 dialysis patients, it is found that each of these items has high sensitivity and specificity with BDI scores ≥12 [33]. In the present study, however, the MHI-5 cut-off point of 52 and the two-item-based cut-off points appeared not to be fit for purpose as screening applications in dialysis patients because of a low sensitivity.

The selection of a cut-off score depends largely on the purpose of use and the consequence of correct and incorrect identification [34]. If the aim is to identify potential cases of depressive disorder, then a high sensitivity measure is asked for. If the goal is to correctly identify patients without a depressive disorder, then a high specificity measure is needed. In epidemiological research focussing on, for instance understanding the association between depressive symptoms and mortality, sensitivity is not per se more important than specificity. In clinical-screening practice, however, high sensitivity is of great importance to correctly identify patients who deserve further attention. Our data suggest that a cut-off value of 70 of MHI-5 can be used safely to discriminate people with and without depressive symptoms. Subsequently, diagnostic psychiatric tools are needed to correctly identify patients with a depressive disorder.

The strength of the present multicentre study is the inclusion of a heterogeneous population, which is a good reflection of clinical practice. A possible limitation is that the BDI and MHI-5 refer to different time frames. The BDI asks for depressive symptoms in the previous 7 days [8], while the MHI-5 queries the duration of feelings in the previous 4 weeks [18]. Therefore, the MHI-5 may underestimate depressive symptoms reported in the BDI if depressive symptoms were only present in the previous week; and may overestimate if depressive symptoms were absent in the previous week but present in the preceding weeks. A second limitation might be the use of the BDI as reference standard. In the present study, we validated the MHI-5 using the BDI, which is a frequently used and valid instrument to measure depressive symptoms but of course not identical to an instrument which ascertains the presence of a depressive disorder. The ‘gold’ standard measure for a depressive disorder is the structured diagnostic psychiatric interview [35]. However, the BDI has

### Table 3. The sensitivity, specificity, positive predicting value and negative predicting value for the presence of depressive symptoms assessed with BDI score ≥16 as reference standard compared with different MHI-5 assessments

<table>
<thead>
<tr>
<th></th>
<th>MHI-5 ≤ 70a (n = 52; 39%)</th>
<th>MHI-5 ≤ 52b (n = 19; 14%)</th>
<th>‘Dumps or blue’c (n = 20; 15%)</th>
<th>‘Dumps and blue’d (n = 9; 7%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sensitivity</td>
<td>0.77</td>
<td>0.40</td>
<td>0.37</td>
<td>0.23</td>
</tr>
<tr>
<td>Specificity</td>
<td>0.72</td>
<td>0.93</td>
<td>0.91</td>
<td>0.98</td>
</tr>
<tr>
<td>Positive predicting value</td>
<td>0.44</td>
<td>0.63</td>
<td>0.55</td>
<td>0.78</td>
</tr>
<tr>
<td>Negative predicting value</td>
<td>0.91</td>
<td>0.84</td>
<td>0.83</td>
<td>0.81</td>
</tr>
</tbody>
</table>

Prior change of having depressive symptoms (BDI ≥ 16) = 23%.

aThe presence of depressive symptoms assessed with MHI-5 cut-off score of <70.
bThe presence of depressive symptoms assessed with MHI-5 cut-off score of ≤52.
cThe presence of depressive symptoms assessed with a score of ≤3 to one of the MHI-5 items ‘down in the dumps’ and ‘downhearted and blue’.
dThe presence of depressive symptoms assessed with a score of ≤3 to both of the MHI-5 items ‘down in the dumps’ and ‘downhearted and blue’.

BDI, Beck Depression Inventory; MHI-5, five-item Mental Health Inventory.

Downloaded from https://academic.oup.com/ndt/article-abstract/27/12/4453/1822302 by guest on 12 April 2019
high sensitivity and specificity for the structured diagnost


In conclusion, the MHI-5 may be considered as a

useful screening instrument for depressive symptoms in
dialysis patients. The MHI-5 cut-off scores used in epide-

miological studies among dialysis patients, however,
appear not to be fit for purpose as screening applications
because of its low sensitivity. Our study suggests a cut-off
of 70 of MHI-5 can be used safely for these purposes.
Future research is needed to study the psychometric prop-
erties of the MHI-5 in dialysis patients in relation to a
structured diagnostic psychiatric interview.

Acknowledgements. The authors gratefully thank all dialysis patients
who participated in this study and Shyrill Pacio, Michelle Sarneckel
dialysis nurses who assisted during data collection. T.O.vd.B. is grateful
who assisted during data collection. T.O.vd.B. is grateful

for use in end-stage renal disease: ESRD as a paradigmatic illness.

References

1. Cohen SD, Norris L, Acquaviva K et al. Screening, diagnosis, and


depression as a correlate of hospitalizations in patients receiving long-


4. Chilcot J, Wellsted D, Farrington K. Depression in end-stage renal

5. Cukor D, Cohen SD, Peterson RA et al. Psychosocial aspects of


6. Riezebos RK, Nauta KJ, Honig A et al. The association of depressive

symptoms with survival in a Dutch cohort of patients with end-stage

7. K/DOQI clinical practice guidelines for cardiovascular disease in


depression. Arch Gen Psychiatry 1961; 4: 561–571.

9. Craven JL, Rodin GM, Little et al. The Beck Depression Inventory

as a screening device for major depression in renal dialysis patients.

10. Hedayati SS, Bosworth HB, Kuchibhatla M et al. The predictive value

of self-report scales compared with physician diagnosis of


screening tools in dialysis patients. Am J Kidney Dis 2005; 46:
919–924.

12. Losman WL, Siegert CE, Korczec A et al. Validity of the Hospital

Anxiety and Depression Scale and the Beck Depression Inventory for
use in end-stage renal disease patients. Br J Clin Psychol 2010;

13. Cuijpers P, Smits N, Donker T et al. Screening for mood and anxiety

disorders with the five-item, the three-item, and the two-item Mental

14. Friedman B, Heisel M, Delavan R. Validity of the SF-36 five-item

Mental Health Index for major depression in functionally impaired,

cient method of identifying major depression and panic disorder in

lupus erythematosus patients using SF-36 Mental Health scores.

17. Yamazaki S, Fukuhara S, Green J. Usefulness of five-item and three-
item Mental Health Inventory to screen for depressive symptoms in
the general population of Japan. Health Qual Life Outcomes 2005;
3: 48.

18. Ware JE, Jr, Sherbourne CD. The MOS 36-item short-form health


depression symptoms, cardiovascular disease events, and mortality

496–504.

20. Lacon E, Jr, Li NC, Guerra-Dean S et al. Depressive symptoms

associate with high mortality risk and dialysis withdrawal in incident
hemodialysis patients. Nephrol Dial Transplant 2012; 27:
2921–2928

21. Lopes AA, Bragg J, Young E et al. Depression as a predictor of

mortality and hospitalization among hemodialysis patients in the

22. Thong MS, Kaptein AA, Krediet RT et al. Social support predicts

survival in dialysis patients. Nephrol Dial Transplant 2007; 22:
845–850.

23. Yamamoto Y, Hayashino Y, Yamazaki S et al. Depressive symptoms

predict the future risk of severe pruritus in haemodialysis patients:

24. Cukor D, Peterson RA, Cohen SD et al. Depression in end-stage

2: 678–687.

25. Aaronson NK, Muller M, Cohen PD et al. Translation, validation,

and norming of the Dutch language version of the SF-36 Health Survey in community and chronic disease populations. J Clin Epide-


ver operating characteristic (ROC) curves. Kidney Int 2009; 76:
252–256.

27. Smits N, Smit F, Cuijpers P et al. Using decision theory to derive

optimal cut-off scores of screening instruments: an illustration expli-

28. Zweig MH, Campbell G. Receiver-operating characteristic (ROC)


29. Chilcot J, Wellsted D, Farrington K. Screening for depression while

23: 2633–2639.

30. Sacks CR, Peterson RA, Kimmel PL. Perception of illness and
depression symptoms, cardiovascular disease events, and mortality

31. Zweig MH, Campbell G. Receiver-operating characteristic (ROC)


32. Holmes WC. A short, psychiatric, case-setting measure for HI

seropositive outpatients: performance characteristics of the 5-item
mental health subscale of the SF-20 in a male, seropositive sample.

33. Troidle L, Wuerth D, Finkelstein S et al. The BDI and the SF36:

determining costs and benefits of mental health screening. Fortschr

34. Ware JE, Jr, SF-36 Physical & Mental Health Summary Scales: A

Medical Center, 1994.

35. Mehlis WC. A short, psychiatric, case-setting measure for HI

seropositive outpatients: performance characteristics of the 5-item
mental health subscale of the SF-20 in a male, seropositive sample.

36. Sheehan DV, Leclerc Y, Sheehan KH et al. The Mini-

International Neuropsychiatric Interview (M.I.N.I.): the development
and validation of a structured diagnostic psychiatric interview for

Received for publication: 29.2.2012; Accepted in revised form: